(NASDAQ: RLMD) Relmada Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Relmada Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RLMD's revenue for 2027 to be $802,633,773, with the lowest RLMD revenue forecast at $802,633,773, and the highest RLMD revenue forecast at $802,633,773.
In 2028, RLMD is forecast to generate $5,714,993,859 in revenue, with the lowest revenue forecast at $5,714,993,859 and the highest revenue forecast at $5,714,993,859.